On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization had granted Emergency Use Listing for NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-Mﾙ adjuvant, for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 caused by SARS-CoV-2.

The EUL pertained to vaccine manufactured and marketed by SII as COVOVAXﾙ, a novel recombinant, adjuvanted SARS-CoV-2 rS Vaccine, in India and licensed territories. An additional EUL filing was under review by the WHO for vaccine to be marketed by Novavax under the brand name Nuvaxovidﾙ.